Bioindustry Ethics
Autor David L Finegold, Cecile Bensimon, Abdallah S Daaren Limba Engleză Paperback – iun 2005
Preț: 1226.73 lei
Puncte Express: 1840
Carte tipărită la comandă
Livrare economică 02-16 iulie
Specificații
ISBN-13: 9780123693709
ISBN-10: 0123693705
Pagini: 382
Dimensiuni: 153 x 228 x 25 mm
Greutate: 20.059999999999999 kg
Editura: ELSEVIER LTD
ISBN-10: 0123693705
Pagini: 382
Dimensiuni: 153 x 228 x 25 mm
Greutate: 20.059999999999999 kg
Editura: ELSEVIER LTD
Public țintă
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health; Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analystsCuprins
Chapter 1: INTRODUCTION
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
Recenzii
"Biotechnology and pharmaceutical companies are often driven by profit goals, but the case studies in Bioindustry Ethics show that this is increasingly not at the expense of ethical integrity. ...lend[s] important insights to other executives and professionals who might be developing their own practices and policies."
- GENOMICS & PROTEOMICS (August 2005)
- GENOMICS & PROTEOMICS (August 2005)